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Abstract
Background: Corona Virus Disease 19 (COVID-19) is a new pandemic, declared a public health emergency by the
World Health Organization, which could have negative consequences for pregnant and postpartum women. The
scarce evidence published to date suggests that perinatal mental health has deteriorated since the COVID-19
outbreak. However, the few studies published so far have some limitations, such as a cross-sectional design and the
omission of important factors for the understanding of perinatal mental health, including governmental restriction
measures and healthcare practices implemented at the maternity hospitals. Within the Riseup-PPD COST Action, a
study is underway to assess the impact of COVID-19 in perinatal mental health. The primary objectives are to (1)
evaluate changes in perinatal mental health outcomes; and (2) determine the risk and protective factors for
perinatal mental health during the COVID-19 pandemic. Additionally, we will compare the results between the
countries participating in the study.
Methods: This is an international prospective cohort study, with a baseline and three follow-up assessments over a
six-month period. It is being carried out in 11 European countries (Albania, Bulgaria, Cyprus, France, Greece, Israel,
Malta, Portugal, Spain, Turkey, and the United Kingdom), Argentina, Brazil and Chile. The sample consists of adult
pregnant and postpartum women (with infants up to 6 months of age). The assessment includes measures on
COVID-19 epidemiology and public health measures (Oxford COVID-19 Government Response Tracker dataset),
Coronavirus Perinatal Experiences (COPE questionnaires), psychological distress (BSI-18), depression (EPDS), anxiety
(GAD-7) and post-traumatic stress symptoms (PTSD checklist for DSM-V).
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Discussion: This study will provide important information for understanding the impact of the COVID-19 pandemic
on perinatal mental health and well-being, including the identification of potential risk and protective factors by
implementing predictive models using machine learning techniques. The findings will help policymakers develop
suitable guidelines and prevention strategies for perinatal mental health and contribute to designing tailored
mental health interventions.
Trial registration: ClinicalTrials.gov Identifier: NCT04595123.
Keywords: COVID-19, Depression, Anxiety, Post-traumatic stress disorders, Postpartum, Pregnancy, Risk factors,
Coping mechanisms
Background
Corona Virus Disease 19 (COVID-19) is a new pan-
demic, declared a public health emergency by the World
Health Organization, which could have negative conse-
quences for pregnant and postpartum women [1].
Although pregnant women do not seem to be more
likely to contract the infection than the general popula-
tion [2–4], obstetric complications have been detected in
infected pregnant women, including the threat of prema-
ture delivery, caesarean delivery and maternal complica-
tions in the postpartum period [3, 5]. Antenatal or
intrapartum vertical transmission (transmission from a
woman to her newborn) might also be possible and can
result in severe consequences for the newborn [6, 7].
In light of the unprecedented crisis brought about by
the COVID-19 pandemic, many perinatal healthcare
practices have been changed in an attempt to reduce the
risk of transmission of the novel coronavirus. These in-
clude cancelation of prenatal and postpartum courses
routinely provided to mothers, adjustments to prenatal
and postpartum appointments, restrictions to the part-
ner’s presence during childbirth and postpartum visit-
ation and, in some cases, face-to-face consultations
replaced by teleconsultations [8, 9]. At the same time,
the confinement and social distancing measures imple-
mented to contain the spread of COVID-19 have been
particularly challenging for women during the perinatal
period [10]. The lack of information about this new
virus, the social isolation and perceived loneliness,
women’s worries over their own health and fear of infec-
tion and transmission of the virus to their fetus/new-
born, together with sudden changes in maternity-care
practices, may result in increased psychological distress
during the perinatal period [11].
The perinatal period (from pregnancy to 1 year after
childbirth) is, in general, a vulnerable time for the acute
onset and recurrence of mental disorders. According to
pre-pandemic data, it is estimated that 1 in 5 women
will develop a mental disorder in the perinatal period
[12–15]. Perinatal depression is the most common dis-
order during pregnancy and the postpartum period and
carries long-lasting adverse effects for women, their
partners and their infants, while also imposing a strong
burden on their families and society as a whole [16]. The
scarce evidence published to date suggests that mental
disorders in pregnant women have increased since the
COVID-19 outbreak. Studies conducted in Canada [17],
China [18], Turkey [19, 20] and Italy [21] report that the
rates of depression and anxiety in pregnant women more
than doubled compared to studies prior to the
pandemic. However, the few studies published so far
have some limitations, such as a cross-sectional design,
small sample sizes, the absence of assessment through-
out the postpartum period or the omission of important
factors for the understanding of perinatal mental health,
including governmental restriction measures, healthcare
practices implemented at the maternity hospitals and
women’s coping strategies. Thus, further research using
prospective comprehensive assessments, examining
women’s psychological distress, as well as potential risk
and protective factors, is needed in order to provide an
evidence-based foundation for the understanding of the
impact of the COVID-19 pandemic on women’s peri-
natal mental health [11, 22].
In order to investigate and recommend best practices
that may mitigate the impact of the COVID-19 pan-
demic on women’s mental health [11, 23], members of
the “Research Innovation and Sustainable Pan-European
Network in Peripartum Depression Disorder – Riseup-
PPD” (Cost Action 18138), funded by the Horizon 2020
Framework Programme of the European Union, estab-
lished the “Perinatal Mental Health and COVID-19
Pandemic” Task Force. Currently, the research team is
conducting an international prospective cohort study
aimed at filling the gaps in research on the impact of the
COVID-19 pandemic on perinatal mental health




The main aim of this prospective study is to investigate
the impact of the COVID-19 pandemic on perinatal
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mental health (depression, anxiety, and post-traumatic
stress symptoms).
The primary objectives are the following:
1) To evaluate changes in perinatal mental health
outcomes (symptoms and indices of clinical risk for
mental disorders) during the COVID-19 pandemic.
We will evaluate the changes in (a) perinatal mental
health symptoms (depression, anxiety and post-
traumatic stress disorder [PTSD]); and (b) clinical risk
indices (proportion of women above the clinical cut-off
point on a validated self-report scale) for depression and
anxiety disorders. We will compare the results to similar
pre-pandemic studies in all the countries. We will also
assess the acute and long-term mental health impact of
different phases of the COVID-19 pandemic by measur-
ing the changes in perinatal mental health outcomes be-
tween the initial survey and the follow-up assessments.
2) To determine the risk and protective factors that
predict perinatal mental health outcomes during
the COVID-19 pandemic.
We will determine the risk and protective factors that
predict PTSD symptoms and the clinical risk of depres-
sion and anxiety disorders (proportion of new cases
above the cut-off point on validated self-report scales in
the follow-up period) during the COVID-19 pandemic.
Factors included in our study were based on recent lit-
erature [24–28] and include demographic variables,
COVID-19 epidemiology and public health measures,
perinatal experiences during the COVID-19 pandemic,
and psychological distress.
Furthermore, additional secondary objectives related
to the impact of COVID-19 on perinatal mental
health will also be examined: the comparison of peri-
natal mental health outcomes between the countries
participating in the study; breastfeeding and its pro-
tective role in perinatal mental disorders; the risk of
perinatal mental disorders in COVID-19-positive
women vs. COVID-19-non-positive women; and fac-
tors associated with the level of distress of women
during the perinatal period.
We hypothesize an increase in negative perinatal men-
tal health outcomes (symptoms and clinical risk) among
women during the COVID-19 pandemic. We also
hypothesize that common risk factors (e.g., low income,
low social support, high level of psychological distress,
previous history of mental disorders) will be associated
with an increase in the clinical risk of depression and
anxiety during the COVID-19 pandemic. Additionally,
we hypothesize that pandemic-related risk factors, such
as being exposed to and/or having a positive diagnosis
for COVID-19, will be associated with increased risk of
perinatal mental disorders.
Study design
This is an international prospective observational cohort
study, with a baseline and three follow-up assessments:
at one, three, and six months post-baseline. The obser-
vation period will be 6 months, from the initial evalu-
ation to the last follow-up assessment. The overall study
will span from 15 June 2020 to 15 June 2021.
Setting
This international study will be carried out in 11
European countries (Albania, Bulgaria, Cyprus, France,
Greece, Israel, Malta, Portugal, Spain, Turkey and the
United Kingdom), Argentina, Brazil and Chile.
Participants
The study population consists of women during the
perinatal period. The rationale is to evaluate women
throughout their pregnancy and during 1 year after
childbirth, for a six-month period (from baseline to
follow-up). Women can, thus, enter the study during
pregnancy or at any time during the first 6 months fol-
lowing childbirth [29].
The inclusion criteria at baseline are:
– Being pregnant or a biological mother of a child six
months of age or younger
– Women 18 years of age or older
– Living in one of the countries involved in the study
– Consenting to participate in the study
The exclusion criteria are:
– Not being currently pregnant or not being the
biological mother of a child six months of age or
younger
– Women younger than 18 years of age
– Living in a country that does not participate in the
study.
– Not consenting to participate in the study
Sample size
We have not set any restrictions on participant en-
rollment. However, a representative sample size was
calculated according to the number of newborns in
the previous year in each country. Thus, we estimated
a minimum sample size of 300 participants per coun-
try, based on an α-level of 0.05 and heterogeneity
equal to 50%.
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Variables and measures
The variables and measures planned for the different
phases of the study are presented in Table 1.
Independent/predictor measures
Oxford COVID-19 government response tracker (OxCGRT)
We will collect the following macro variables related to
the COVID-19 epidemiological data and public health
measures publicly available for each of the participating
countries from the Oxford COVID-19 Government Re-
sponse Tracker (OxCGRT) [30]: (1) Population; (2)
Number of confirmed deaths; (3) Number of confirmed
COVID-19 cases; (4) Case fatality rate; (5) Government
Stringency Index [30], a composite score from 0 to 100
that considers the strictness of containment strategies
(closures, movement restrictions) and information cam-
paigns; (6) Containment and Health Index [30], a com-
posite measure which combines ‘lockdown’ restrictions
and closures with measures such as testing policy and
contact tracing, short term investment in healthcare, as
well investments in vaccines; and (7) Stay-at-home re-
quirements or household lockdowns, which include: (a)
No measures; (b) Recommended not to leave the house;
(c) Required to not leave the house with exceptions for
daily exercise, grocery shopping, and ‘essential’ trips; (d)
Required to not leave the house with minimal exceptions
(e.g., allowed to leave only once every few days, or only
one person can leave at a time, etc.). These data will be
extracted according to the date of the baseline and sub-
sequent follow-up analysis.
Demographics
This questionnaire will include a subset of 14 questions
about the women’s date and country of birth; state/city
of residence; educational level; number of previous preg-
nancies; number of biological children (including still-
births); number of people living at home (adults and
children); marital status; cohabitation with partner; char-
acteristics of the home (inside and outside spaces in
square meters); and living environment changes since
the beginning of the pandemic.
Coronavirus perinatal experiences (COPE) questionnaires
In order to assess the experiences of the women during
the COVID-19 pandemic, a modified version of the Cor-
onavirus Perinatal Experiences - Impact Survey (COPE-
IS) [31] will be administered at the baseline assessment.
The questionnaire assesses several areas of impact: peri-
natal experiences related to the COVID-19 pandemic;
exposure and symptoms; financial impact; social support
impact; social distancing and activity restrictions; coping
and adjustment; emotional impact; physical and mental
health history and substance use.
In the follow-up assessments, the women’s experiences
will be measured using a modified version of the Cor-
onavirus Perinatal Experiences Scale - Impact Update
(COPE-IU) [32] and the Coronavirus Perinatal
Table 1 Variables and measures used in each phase of the study
Variables Measures Baseline T1 T2 T3
Independent/predictor
COVID-19 epidemiology and public health measures OxCGRT X X X X
Demographic variables 14 questions X
Perinatal health care experiences related with COVID-19 COPE-IS X
COVID-19 exposures and symptoms COPE-IS; COPE-IU X X X X
COVID-19 financial impact COPE-IS; COPE-CF X X X X
COVID-19 social support impact COPE IS; COPE-CF X X X X
COVID-19 coping strategies COPE-IS; COPE-IU X X X X
COVID-19 emotional impact COPE-IS; COPE-IU X X X X
Health background, mental health, and substance use COPE-IS X
Psychological distress BSI-18 X X X X
Dependent/outcome
Depression symptoms EPDS X X X X
Anxiety symptoms GAD-7 X X X X
PTSD symptoms 10 questions from PTSD Checklist for
DSM-5 included in COPE-IS; COPE-IU
X X X X
T1: 1-month follow-up; T2: 3-month follow-up; T3: 6-month follow-up; PTSD: Post-traumatic Stress Disorder; OxCGRT: Oxford COVID-19 Government Response
Tracker; COPE-IS: Coronavirus Perinatal Experiences - Impact Survey; COPE-IU: Coronavirus Perinatal Experiences Scale - Impact Update; COPE-CF: Coronavirus
Perinatal Experiences Scale - Care Follow Up; BSI-18: Brief Symptom Inventory-18; EPDS: Edinburgh Postnatal Depression Scale; GAD-7: Generalized Anxiety
Disorder Screener
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Experiences Scale - Care Follow Up (COPE-CF) [33].
The COPE-IU evaluates exposure to COVID-19, symp-
toms, impact on daily life, experiences and feelings,
whereas the COPE-CF evaluates perceived support and
care and the social and financial impact of the
pandemic.
The sections included in the modified version of the
COPE-IS [31], COPE-IU [32]and COPE-CF [33]are de-
scribed below.
Perinatal health care experiences related to COVID-
19 Twenty-six items regarding parity, health problems
during pregnancy, type of pregnancy, prenatal and post-
partum care support and resources available during this
period, changes experienced as a result of the COVID-
19 outbreak, and possible concerns about changes in
family/friend support, medical care during childbirth
and the child’s health. For postpartum women specific-
ally, the survey also includes questions about the infant’s
place of birth, breastfeeding, changes experienced in
birth plans and level of distress experienced related to
changes in birth and postpartum plans [31].
COVID-19 exposures and symptoms Six items about
(1) the diagnosis of COVID-19; (2) any symptoms com-
patible with the coronavirus disease; (3) contact with
someone who has been diagnosed with COVID-19; (4)
any death of family or friends due to COVID-19; (5) the
level of distress about COVID-19-related symptoms or
potential illness: (5a) their own illness or (5b) in their
friends and family [31, 32].
COVID-19 financial impact Two items about (1) the
current employment situation and (2) the financial im-
pact of the COVID-19 outbreak [31, 33].
COVID-19 social support impact Six items about (1)
seeking support, (2) support provided, (3) need for support,
(4) perceived support; (5) level of distress experienced with
disruptions to social support due to the COVID-19 pan-
demic; and (6) number of weeks participants have been ob-
serving the lockdown guidance [31, 33].
COVID-19 coping strategies A total of 23 items re-
garding potential coping strategies (problem-focused or
emotion-focused) to cope with the stress related to the
COVID-19 pandemic (for example, “getting a good
night’s sleep”; “talking with friends”). The participants
must indicate all the strategies that they are implement-
ing [31, 32].
COVID-19 emotional impact Four items assessing the
subjective impact of the COVID-19 pandemic. The
questions include: (1) overall level of impact on daily life
due to the COVID-19 pandemic; (2) overall level of
stress related to the COVID-19 outbreak; (3) perceived
positive or negative impact of the COVID-19 pandemic;
and (4) how long participants think it will take for things
to go “back to normal”? [31, 32].
Physical and mental health history and substance use
Thirteen items addressing: 1) the women’s and family
(partner, child or other members of the household) his-
tory of the following medical conditions: respiratory
problems, diabetes, heart disease or hypertension, lung
disease; liver disease; cancer; disease compromising the
immune system; mood and/or anxiety disorders; 2)
whether currently receiving treatment for mental disor-
ders (for example, depression, anxiety, stress, ADHD, bi-
polar disorder, eating disorder or PTSD); 3) current
substance use; and 4) current treatment of medical con-
ditions [31].
Brief symptom Inventory-18
The Brief Symptom Inventory-18 (BSI-18), omitting sui-
cidality, will be used to evaluate psychological distress
[34] in the last week. The BSI-18 is an 18-item self-
report questionnaire which includes a summary scale of
overall distress, the Global Severity Index (GSI), and
three subscales: depression, anxiety, and somatization.
Each item is rated on a 5-point scale, with distress rat-
ings ranging from 0 (not at all) to 4 (extremely). For the
purposes of the current study, only the GSI will be ex-
amined. The GSI level is the summed score of all the
items [34].
Dependent/outcome measures
Edinburgh postnatal depression scale The Edinburgh
Postnatal Depression Scale (EPDS) [35] is the most
widely used self-report scale designed to identify women
at risk for perinatal depression [36]. The 10-item scale
indicates how women felt during the previous week. The
items assess symptoms of sadness, anxiety and thoughts
about death. Scores range from 0 to 30. The depression
level is the sum score of all the items, and higher scores
indicate greater symptom severity. A threshold of 13 or
more will be used to identify clinically significant symp-
toms [37]. Although a number of cut-off points have
been used in different populations [38], maximum ac-
curacy with a probable diagnosis of depressive disorder
has been shown at this cut-off point in reviews of inter-
national EPDS validation studies [36–39].
Generalized anxiety disorder screener
Symptoms of anxiety will be evaluated using the vali-
dated self-report questionnaire Generalized Anxiety Dis-
order Screener (GAD-7) [40], which is based on criteria
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from the Diagnostic and Statistical Manual of Mental
Disorders (DSM)-IV and DSM-IV-TR [41]. Even though
GAD-7 was developed for generalized anxiety disorder,
it is also used as a measure for anxiety for research pur-
poses [42, 43] and clinical management for antenatal
and postpartum mental health [44]. The seven items
assess worry, tension, restlessness, and irritability. The
GAD-7 total score ranges from 0 to 21. The anxiety level
is the sum score of all the items, with higher scores
reflecting greater anxiety severity. We will use a threshold
of 10 or more points for a participant to be considered as
belonging to a clinical range [14, 40]. The GAD-7 has
shown good reliability and construct validity in pregnancy
and the postpartum period [40, 45, 46].
Post-traumatic stress disorder (PTSD) checklist
Post-traumatic stress symptoms associated with COVID-
19 will be evaluated via a subset of 10 questions from
the Post-Traumatic Stress Disorder (PTSD) checklist for
DSM-5 [47, 48]. These 10 questions ask participants to
indicate the extent to which they experienced: (1) Feel-
ing super alert or watchful or on guard; (2) Feeling
jumpy or easily startled; (3) Having difficulty concentrat-
ing; (4) Trouble experiencing positive feelings; (5) Feel-
ing guilty or blaming yourself; (6) Feeling irritable, angry
or aggressive; (7) Repeated disturbing and unwanted
thoughts about the COVID-19 outbreak; (8) Repeated
disturbing dreams about the COVID-19 outbreak; (9)
Trying to avoid information or reminders about the
COVID-19 outbreak; and (10) Taking too many risks or
doing things that could cause you harm. All items refer
to the previous seven days and are answered on a five-
point Likert scale, ranging from 0 (Not at all) to 4
(Extremely) with possible total scores ranging from 0 to
40. Higher scores indicate greater symptom severity. The
PTSD symptom level is a summed score of all the items
[47]. The subset of questions from the PTSD checklist
are included in the COPE-IS and COPE-IU question-
naires [31, 32].
Validation of the questionnaires
We will use available validated versions of the EPDS,
GAD-7 and PTSD DSM-5 checklist in the official
language of all the participating countries. However,
COPE-IS, COPE-IU and COPE-CF are newly developed
measures, and psychometric properties are yet to be
established. Scoring procedures also need to be deter-
mined. The COPE questionnaires were originally avail-
able in English and translated to Spanish and German.
Thus, researchers from each country involved in the
study performed the translation and cultural adaptation
of the questionnaires from English into the official lan-
guage of their country, following several methodological
steps, defined a priori, as detailed in Table 2. No major
discrepancy was identified in any of the cross-cultural
adaptations.
Ethical standards
This study is conducted according to the principles
expressed in the Declaration of Helsinki. Ethical ap-
proval was obtained from all the countries before start-
ing the project. Handling of the study data will comply
with all the national required standards for data protec-
tion. Electronic informed consent will be obtained from
all the participants, and the confidentiality of all the in-
formation provided will be ensured.
Some survey questions can elicit changes in the emo-
tional state of participants. In order to address this issue,
a debriefing procedure will be made available; at the end
of the survey, a list of up-to-date services and resources
will be provided for each country covering a range of
needs, from information about the COVID-19 pandemic
to the general mental health and perinatal care services
available in each country. Additionally, contact informa-
tion for the lead research team for each country will be
given in case participants would like to request add-
itional information. The researchers will publish the re-
sults of the study on the website and will send
information about the global results of the study to the
participants upon request.
Data collection
Participants will be recruited through social media ad-
vertising (Twitter, Facebook, Instagram, LinkedIn,
ResearchGate, WhatsApp, etc.), networks of organiza-
tions (including universities, health centers, NGOs work-
ing in the field of perinatal mental health), policymakers,
local organizations, and other stakeholders (using the
network provided by the Riseup-PPD), as well as per-
sonal networks of colleagues and acquaintances of the
research team members, and direct contact by mobile
message or email.
Participants will be asked to click on the project web-
site link (see the general project website: https://
momsduringcovid.org) to be directed to the online ques-
tionnaire for their specific country. First, they will read
an electronic consent form presenting an overview of
the study aims, content of the questions asked, potential
risks and benefits, and ethical aspects of the study (i.e.,
Table 2 Cross cultural adaptation of the COPE questionnaires
• Adaptation of “demographic variables”
• Forward and backward translation from the original version
• A pilot study with a small (N≥ 4) sample of pregnant women and new
mothers (to assure comprehensibility of the items as intended)
• Revision of the instrument by an expert committee (in the perinatal
field) in each country (N≥ 2 persons)
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voluntary participation, confidentiality and secure stor-
age of the data, and absence of any type of compensa-
tion). At the bottom of the form, they will be asked to
confirm a set of eligibility criteria and to provide their
consent to access the study. Participants who do not
meet the predefined inclusion criteria will be directed to
a message thanking them for their interest and inform-
ing them of the required eligibility criteria for participa-
tion in the study.
The baseline questionnaire is estimated to take ap-
proximately 20 min to complete. Eligible participants
who complete the baseline questionnaire will be invited
to provide their email or phone number to be contacted
to participate in the three follow-up assessments. Partici-
pation in the follow-ups will be optional and participants
will need to provide their consent to be contacted by
email or phone (text messages only). Attached to this re-
quest, we will provide a clear plan to guarantee confi-
dentiality and protection of the contact information
provided (this information will also be provided in the
Informed Consent).
Data analysis
Patterns of missingness in the data will be studied and
the Expectation-Maximization algorithm will be imple-
mented to impute missing data. Attrition analyses will
be carried out to examine differences between partici-
pants who completed all the assessments and those who
did not. Descriptive statistics will be examined for the
study variables for all the assessment times. Measure-
ment equivalence will be studied in order to ensure we
are measuring the same variables across countries.
Changes in mental health between baseline and the
follow-ups will be examined by testing latent growth
curve models for each outcome. Moreover, the relation-
ships between the rates of change in predictors (i.e., risk
and protective factors) and mental health results during
the follow-up will be analyzed. Multilevel analyses will
be performed to control the moderation of demographic
variables in those interrelations. Regarding the overall fit
of these models, Satorra-Bentler χ2, CFI, RMSEA and
the confidence interval for the RMSEA statistics will be
calculated. Lagrange multipliers and the Wald test will
be performed sequentially to improve the fitness of the
models, following the hypotheses of the study. Standard-
ized coefficients and measurement equations with scores
in R2 will be reported. These analyses will be undertaken
using the statistical program EQS. 6.3.
To determine the risk and protective factors to predict
perinatal mental health outcomes during the COVID-19
pandemic, a random sample of 70% of the data will be
used to derive the machine learning algorithms includ-
ing regularized logistic regression, random forest, deci-
sion tree, and gradient boosting to predict the risk of
PPD, and their performance, and the remaining 30% for
validation. First, in the derivation sample, all the predic-
tors described above will be entered into the models to
estimate the probability of depression or anxiety or
PTSD. Beginning with a model containing all potential
covariates, the variable with the least significant P value
will be removed and tested using the likelihood-ratio test
until all variables left in the model significantly (at
alpha = 0.05) contribute to the model.
In regularized logistic regression models, results will
be presented as odds ratio (OR) with 95% confidence in-
tervals (CIs). The R2 will be used to calculate the pro-
portion of the explained variance of clinical outcomes by
the selected predictors. The different aspects of model
performance will be studied, including calibration and
discrimination. Calibration will be assessed using the
Brier score and by plotting the non-parametric estimate
of the association between the observed frequencies and
the predicted probabilities. The receiver operating char-
acteristic (ROC) curves (and the corresponding area
under the ROC curve—AUC) will be calculated to test
for discrimination. To correct optimism, internal valid-
ation will be performed for each model using the boot-
strap procedure with 500 bootstrapped samples. The
final models will be selected to derive scores for clinical
use, and nomograms will be created. Criteria for this se-
lection will include both discriminant ability (defined by
the AUC) and model simplicity. Finally, the coefficients
(scores) derived from the derivation cohort will also be
validated in the validation cohort. These statistical ana-
lyses will be carried out in R and Python. The analyses
will conform to the reporting standards of transparent
reporting of a multivariable prediction model for indi-
vidual prognosis or diagnosis (TRIPOD) [49].
Dissemination and data sharing plan
To enhance data reporting transparency, this study will
be reported in accordance with the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) Statement: Guidelines for Reporting Observa-
tional Studies) [50].
Data and resources will be shared with other eligible
investigators through academically established means.
The datasets used and/or analyzed during the study will
be available upon reasonable request. The results from
this work will be published as full-length, peer-reviewed
manuscripts and presented at national and international
conferences.
Discussion
Several studies on COVID-19 and pregnancy have been
recently published, but the impact of this pandemic on
perinatal mental health is yet to be properly evaluated.
Currently, no international prospective cohort study has
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been published on the impact of COVID-19 on perinatal
mental health [51].
An international collaboration and global perspective
will enrich the understanding of the impact of COVID-
19 on perinatal mental health, while examining potential
similarities and differences across the countries involved.
The current investigation aims to offer new insights into
this new research domain. Further, it will address some
of the existing gaps in this field: (1) the international
nature of the study will enhance the external validity of
the findings by using multi-site comparable instruments;
(2) the governmental restriction measures during the
COVID-19 pandemic (e.g. Government Stringency
Index; Containment and Health Index) will be extracted
from the Oxford COVID-19 Government Response
Tracker (OxCGRT) [30] dataset; (3) the participants will
be women during the perinatal period; (4) we will assess
healthcare practices and potential risk and protective
factors cited in the literature as relevant for perinatal
mental disorders; and (5) the study will include four as-
sessments (baseline and three follow-ups) during a six-
month period. This will enable us to address the impact
of the different countries’ governmental restriction mea-
sures on the perinatal mental health outcomes, to iden-
tify the variability in risk and protective factors over
time, and to examine their association with mental
health outcomes. Furthermore, we will develop predict-
ive models for perinatal mental health outcomes using
machine learning approaches [52–54].
The present study will also have some limitations.
First, our sample will not be a random probability sam-
ple, since there was a need to rapidly obtain a sample of
perinatal women, so non-purposive sampling was used.
Second, using online surveys limits the participation of
some important groups in the population, including
those women with no access to internet or social media,
low educational level (limiting comprehension of the
questions), or not fluent in the official language of the
country of residence. It is also possible that the survey
attracts participants interested in the topic and affected
by psychological factors (e.g., need for gratification,
personality dispositions), creating the possibility of a
sampling bias [55]. Last, all perinatal mental health out-
comes will be evaluated using valid self-report screening
instruments instead of clinician administered interviews,
which may result in over- or under-estimation of peri-
natal mental health disorder prevalence and incidence.
Significance and practical implications of the study
A previous position paper highlights that an immediate
public health priority is evidence-based research on the
mental health effects of the COVID-19 pandemic in vul-
nerable populations [22], such as women during the
perinatal period [11]. Furthermore, there is an urgent
need for research to address how to mitigate the mental
health consequences of COVID-19 in women during the
perinatal period [22].
The findings will provide critical information regard-
ing the risk and protective factors for perinatal mental
health disorders during the COVID-19 pandemic. The
results of this study will offer clarification on the impact
of the pandemic on women during the perinatal period,
allowing the development of comprehensive models for
the prediction of perinatal mental disorders, specifying
the contribution of each risk and protective factor and
contributing to the design of tailored interventions to
support women during the COVID-19 pandemic. This
will allow perinatal healthcare providers to assess
women at risk of developing mental health disorders
during the pandemic and provide early intervention as
well as develop preventive measures. In addition, the
findings of the study will assist policymakers and health-
care providers in developing guidelines and preventive
interventions for perinatal mental disorders in future
pandemics.
Conclusion
In conclusion, this international prospective cohort
study aims to robustly/longitudinally assess the impact
of the COVID-19 pandemic on women’s perinatal men-
tal health. This information will provide vital under-
standing of the impact of the pandemic on perinatal
mental health, which may aid in the implementation of
tailored interventions and provide empirical evidence for
policymakers on future decisions in similar scenarios as
well as on future planning of interventions.
Abbreviation
COVID-19: Corona Virus Disease 19
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